Fintel reports that on May 21, 2024, Leerink Partners initiated coverage of Q32 Bio (NasdaqGM:QTTB) with a Outperform recommendation.
Analyst Price Forecast Suggests 60.43% Upside
As of May 8, 2024, the average one-year price target for Q32 Bio is 48.45. The forecasts range from a low of 45.45 to a high of $52.50. The average price target represents an increase of 60.43% from its latest reported closing price of 30.20.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Q32 Bio is 1MM. The projected annual non-GAAP EPS is -0.70.
What is the Fund Sentiment?
There are 40 funds or institutions reporting positions in Q32 Bio. This is an increase of 35 owner(s) or 700.00% in the last quarter. 
The put/call ratio of QTTB is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
Orbimed Advisors holds 2,253K shares representing 18.89% ownership of the company.
Atlas Venture Life Science Advisors holds 2,092K shares representing 17.54% ownership of the company.
Carlyle Group holds 1,103K shares representing 9.24% ownership of the company.
Vivo Capital holds 370K shares representing 3.10% ownership of the company.
Arch Venture holds 320K shares representing 2.69% ownership of the company.
Q32 Bio Background Information
(This description is provided by the company.)
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
